Showing results (31-40 of 75) with videos related to

Sort By:
Pageof 8
Therapeutic Advances in Medical Oncology|December 18, 2020
Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II-III HER2-negative breast cancer: a 10-year, retrospective analysisRiccardo Lobefaro, Emma Zattarin, Federico Nichetti, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2023
Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trialsAlessandra Raimondi, Federico Nichetti, Arndt Stahler, et al.
NPJ Precision Oncology|December 15, 2025
Benchmarking progression-free survival ratio as primary endpoint in precision oncology clinical trialsFederico Nichetti, Jennifer Hüllein, Pauline du Rusquec, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2023
Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 StudyGiovanni Randon, Yoshiaki Nakamura, Rona Yaeger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2023
Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract CancersTin-Yun Tang, Federico Nichetti, Ben Kaplan, et al.
Journal of Geriatric Oncology|December 16, 2018
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world studyValentina Fanotto, Lorenzo Fornaro, Roberto Bordonaro, et al.
Cancers|March 12, 2020
Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast CancerClaudio Vernieri, Michele Prisciandaro, Federico Nichetti, et al.
The Oncologist|May 10, 2018
Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use ProgramChiara Cremolini, Daniele Rossini, Erika Martinelli, et al.
European Journal of Cancer (Oxford, England : 1990)|November 4, 2023
Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LVFilippo Pietrantonio, Francesca Bergamo, Daniele Rossini, et al.
European Journal of Cancer (Oxford, England : 1990)|April 6, 2021
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access programArsela Prelaj, Achille Bottiglieri, Claudia Proto, et al.
Pageof 8